Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.80 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.80 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.80 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.80 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.80 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.80 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 0.80 |
| ▸ | CDK2 | P24941 | 19/20 | 0.98 |
| ▸ | CDK9 | P50750 | 13/20 | 0.98 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.80 |
| ▸ | CDK1 | P06493 | 2/20 | 0.80 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.80 |
| ▸ | CDK7 | P50613 | 2/20 | 0.80 |
| ▸ | CCNH | P51946 | 2/20 | 0.80 |
| ▸ | CIT | O14578 | 1/20 | 0.80 |
| ▸ | CASK | O14936 | 1/20 | 0.80 |
| ▸ | AURKA | O14965 | 1/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6183918 | 1.00 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| Hydrochloric Acid SCHEMBL6183623 | 1.00 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL4730239 | 0.99 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL4733685 | 0.99 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL4731289 | 0.99 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL6911525 | 0.90 | CDK2 (0.83) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL6911788 | 0.90 | CDK2 (0.83) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| Bms-387032 SCHEMBL20583046 | 0.90 | CDK2 (0.98) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| Bms-387032 SCHEMBL187401 | 0.89 | CDK2 (1.00) | CDK2CDK9CCNE2CCNE1CCNT1 | |
| SCHEMBL14067131 | 0.89 | CDK2 (0.82) | CDK2CDK9CCNE2CCNE1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3347018-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017044858-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-1240166-B1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6534531-B2 | Thiazole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6515004-B1 | Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1240166-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2001044242-A9 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001044242-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142507-B2 | Inhibitors of cyclin-dependent kinases | CDK1, CDK13, CDK3 | PRKD3 508/4885MET 3019/4885CDK4 28/4885 |
| US-20200172499-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | PRKD3 508/4885MET 3019/4885CDK4 28/4885 |
| US-20020061915-A1 | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | NR5A1, CYP17A1, CYP21A2 | PRKD3 2565/4885MET 2163/4885CDK4 3822/4885 |
| US-20180362483-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | PRKD3 508/4885MET 3019/4885CDK4 28/4885 |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | PRKD3 508/4885MET 3019/4885CDK4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.